Pharmacokinetics Guides

Comprehensive PK parameter guides for 198+ drugs. Each guide includes key pharmacokinetic data, dosing information, and an interactive simulator.

All (198)Anesthesia (1)CNS (1)Cardiology (10)Cardiology / Nephrology (1)Cardiovascular (3)Cardiovascular / Lipid Disorders (1)Dermatology / Chronic pruritic disorders (1)Dermatology / Immunology (1)Emergency Medicine / Opioid Overdose (1)Endocrinology (8)Gastroenterology (1)Genetic Medicine / RNA Therapeutics (1)HIV / Infectious Disease (1)HIV Prevention (1)Hematology (2)Hematology / Hemophilia A (1)Hematology / Transplantation (1)Hereditary Transthyretin Amyloidosis (hATTR) (1)Hypertension / Urology (1)Immunology (16)Immunology / Antiparasitic / Oncology (adjuvant) (1)Immunology/Dermatology (1)Infectious Disease (14)Infectious Disease - Critical Care (1)Infectious Disease - Tuberculosis (2)Infectious Disease / Critical Care (2)Infectious Disease / Transplant (1)Metabolic (3)Neurology (4)Neurology / Epilepsy (1)Obesity / Weight Management (1)Obstetrics (1)Obstetrics / Maternal Medicine (1)Obstetrics / Maternal-Fetal Medicine (3)Oncology (50)Oncology / Acute myeloid leukemia (1)Oncology / Breast Cancer (1)Oncology / HER2+ Breast Cancer (3)Oncology / Metastatic Colorectal Cancer (1)Oncology / NSCLC (3)Oncology / Neuro-oncology (1)Oncology / Ovarian Cancer (2)Oncology / Prostate Cancer (1)Oncology supportive care (1)Oncology supportive care / toxicology (1)Oncology — Acute Lymphoblastic Leukemia (1)Ophthalmology (2)Opioid Overdose / Emergency Medicine (1)Pain (2)Pain / Neurology (1)Pediatric Infectious Disease / Neonatology (1)Platform (5)Platform QA (1)Psychiatry (2)Psychiatry / CNS (1)Psychiatry / Neurology (1)Pulmonology (3)Rare Disease (4)Rare disease (1)Respiratory (1)Respiratory / Inflammatory disease (1)Rheumatology (1)Transplant (5)Transplant / Immunosuppression (1)Transplant Immunosuppression (1)Transplant Medicine / Infectious Disease (1)Transplantation / Infectious Disease (1)Transplantation / Nephrology (1)Transthyretin Amyloidosis (ATTR) (1)Tuberculosis (1)Type 2 Diabetes (1)Type 2 Diabetes / Metabolic Disease (1)

OncologyPK/PD model with 2-compartment Michaelis-Menten PK and Friberg myelosuppression PD

5-FU A Tool for Predicting Pharmacokinetic–Pharmacodynamic/Toxicodynamic Responses Pharmacokinetics Guide

Colorectal cancer and other gastrointestinal malignancies treated with infusional 5-FU regimens

Fluoropyrimidine antimetabolite

5-Fluorouracil Pharmacokinetics Guide

Cancer chemotherapy

Antimetabolite

ADC Effector Function Model Pharmacokinetics Guide

Solid Tumors

ADC

OncologyPopulation PK

ADCs Pharmacokinetics Guide

HER2-positive breast cancer, NSCLC, gastric/GEJ cancer

Antibody-Drug Conjugate (ADC)

BTK Degrader Pharmacokinetics Guide

B-cell Malignancies

PROTAC

BTK Targeted Degrader Pharmacokinetics Guide

B-cell Malignancies

PROTAC

OncologySequential metabolite PopPK (capecitabine to 5'-DFCR to 5'-DFUR to 5-FU)

Capecitabine and 5-FU Pharmacokinetics Guide

Colorectal cancer, breast cancer, and gastric or gastroesophageal adenocarcinoma

Fluoropyrimidine / Oral Prodrug

Cisplatin Pharmacokinetics Guide

Cancer chemotherapy

Platinum

Oncology2-CMT PopPK

Darzalex (Daratumumab) Pharmacokinetics Guide

Multiple myeloma

mAb

OncologyPopulation PK

Dato Pharmacokinetics Guide

TROP2-positive metastatic breast cancer and other TROP2-expressing solid tumors

Antibody-Drug Conjugate (ADC)

OncologyPopulation PK (2-CMT ADC parallel linear+MM + 1-CMT Payload)

Datopotamab Deruxtecan (Datroway) Pharmacokinetics Guide

Locally advanced or metastatic non-squamous NSCLC (TROPION-Lung08), HR+/HER2-low/negative metastatic breast cancer (TROPION-Breast01), and triple-negative breast cancer; TROP2-directed ADC with DXd payload

Antibody-Drug Conjugate (ADC)

Oncology3-compartment PopPK with covariate effects

Docetaxel Pharmacokinetics Guide

Breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, and head and neck cancer

Taxane / Microtubule stabilizer

Doxorubicin Pharmacokinetics Guide

Cancer chemotherapy

Anthracycline

OncologyPopulation PK (Sequential 2-CMT ADC + 1-CMT Payload)

Enhertu Pharmacokinetics Guide

HER2-positive breast cancer, gastric/gastroesophageal adenocarcinoma, NSCLC

Antibody-Drug Conjugate (ADC)

Oncology1-CMT PopPK

Ibrance (Palbociclib) Pharmacokinetics Guide

HR+/HER2- metastatic breast cancer

Small Molecule

Imatinib Pharmacokinetics Guide

CML / GIST

Small Molecule

Oncology1-CMT PopPK

Imbruvica (Ibrutinib) Pharmacokinetics Guide

Chronic lymphocytic leukemia

Small Molecule

Oncology2-CMT PopPK

Imfinzi (Durvalumab) Pharmacokinetics Guide

Non-small cell lung cancer

mAb

Infigratinib Pharmacokinetics Guide

Cholangiocarcinoma

Small Molecule

Oncology2-CMT PopPK

Keytruda (Pembrolizumab) Pharmacokinetics Guide

Melanoma and non-small cell lung cancer

mAb

Keytruda Pharmacokinetics Guide

Cancer immunotherapy

PD-1 inhibitor

Oncology1-CMT PopPK

Lynparza (Olaparib) Pharmacokinetics Guide

BRCA-mutated ovarian cancer

Small Molecule

Methotrexate High-Dose Pharmacokinetics Guide

Cancer/RA

Antimetabolite

Oncology Dose Selection Tool Pharmacokinetics Guide

Solid Tumors

Small Molecule

Oncology2-CMT PopPK

Opdivo (Nivolumab) Pharmacokinetics Guide

Melanoma and non-small cell lung cancer

mAb

OncologyPBPK-PD

PBPK-PD Topo1-Based ADC Pharmacokinetics Guide

Solid tumors (HER2-positive and Trop-2-positive cancers)

Antibody-Drug Conjugate

OncologyPBPK-PD Model

PBPK-PD Topo1-Based ADC Pharmacokinetics Guide

Solid tumors (breast, lung, gastric, colorectal cancer)

Antibody-Drug Conjugate (ADC)

OncologyPBPK-PD Model

PBPK-PD Topo1-Based ADC Pharmacokinetics Guide

Solid tumors (breast, lung, gastric, colorectal cancer)

Antibody-Drug Conjugate (ADC)

OncologyPBPK-PD

PBPK-PD of ADCs Pharmacokinetics Guide

Exposure and ILD risk assessment for trastuzumab deruxtecan and related ADC therapy

Antibody-Drug Conjugate (ADC)

Paclitaxel Pharmacokinetics Guide

Cancer chemotherapy

Taxane

Oncology2-CMT PopPK

Perjeta (Pertuzumab) Pharmacokinetics Guide

HER2-positive breast cancer

mAb

Oncology2-compartment PopPK

Pertuzumab Pharmacokinetics Guide

HER2-positive solid tumors

Monoclonal antibody

Oncology1-CMT PopPK

Pomalyst (Pomalidomide) Pharmacokinetics Guide

Multiple myeloma

Small Molecule

Oncology1-CMT PopPK

Revlimid (Lenalidomide) Pharmacokinetics Guide

Multiple myeloma

Small Molecule

OncologySemi-mechanistic PK/PD

Ruc Pharmacokinetics Guide

BRCA-mutant and HRD+ breast cancer

PARP inhibitor

OncologyPopulation PK (Triple-analyte: ADC + SN-38 payload + total antibody)

Sacituzumab Govitecan (Trodelvy) Pharmacokinetics Guide

Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer; TROP2-directed ADC with SN-38 payload

Antibody-Drug Conjugate (ADC)

OncologyTwo-Compartment with Time-Dependent Clearance

Serplulimab (HLX10) Population Pharmacokinetics Guide

Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Monoclonal Antibody (anti-PD-1)

T-cell Engager Pharmacokinetics Guide

Hematologic Malignancies

mAb

OncologyMinimal PBPK-TMDD with Target Shedding

TMDD Model Pharmacokinetics Guide

HER2-positive Breast Cancer

Monoclonal Antibody (Anti-HER2)

Oncology1-CMT PopPK

Tagrisso (Osimertinib) Pharmacokinetics Guide

EGFR-mutated non-small cell lung cancer

Small Molecule

Oncology2-CMT PopPK

Tecentriq (Atezolizumab) Pharmacokinetics Guide

Non-small cell lung cancer

mAb

OncologyMinimal PBPK-TMDD

Trastuzumab (Herceptin) PBPK-TMDD Pharmacokinetics Guide

HER2-positive breast cancer

Anti-HER2 Monoclonal Antibody

Trastuzumab Pharmacokinetics Guide

HER2+ Breast Cancer

mAb

Trastuzumab Pharmacokinetics Guide

HER2+ Breast Cancer

mAb

Tumor Exposure Analysis Model Pharmacokinetics Guide

Solid Tumors

mAb

Oncology1-CMT PopPK

Verzenio (Abemaciclib) Pharmacokinetics Guide

HR+/HER2- metastatic breast cancer

Small Molecule

Oncology1-CMT PopPK

Xtandi (Enzalutamide) Pharmacokinetics Guide

Metastatic castration-resistant prostate cancer

Small Molecule

OncologyPopulation PK

lenvatinib_Gupta_26879594 Pharmacokinetics Guide

Advanced renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer

Multikinase Inhibitor (TKI)

OncologyPopPK (2-compartment)

rucaparib ok model Pharmacokinetics Guide

Ovarian cancer, metastatic castration-resistant prostate cancer (mCRPC)

PARP Inhibitor

OncologyPopulation PK/PD

rucaparib Pharmacokinetics Guide

PARP-targeted therapy in advanced solid tumors including ovarian cancer

PARP Inhibitor

Build Your Own PK/PD Simulator

PKPDBuilder uses AI to transform published pharmacometric literature into interactive Shiny applications. No coding required.

Get Started Free